A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA Joins Coalition Working to Expand Genetic Testing Access
OCRA recently joined the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT), which is working to ensure genetic testing access for all who may carry inherited mutations that increase the risk … Continued
The Overview: November 2024
International Forum on Ovarian Cancer Aims to Accelerate Progress Ovarian Cancer Research Alliance (OCRA) President and CEO Audra Moran, along with members of the OCRA team, joined leading scientists and … Continued
Advocate’s Corner: November 2024
Closing out 2024 and Looking Ahead to 2025 As we approach the close of this year’s legislative calendar, the urgency surrounding the federal budget process cannot be overstated. If action … Continued